Talacotuzumab ELISA Kit (KDD72501)

Colorimetric

Plasma, Serum

Quantitative

0.31-5 μg/mL

0.156 μg/ml

CV<20%

80-120%

2-8 ℃

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Talacotuzumab (TAL, JNJ-56022473) is an IgG1 monoclonal antibody targeting CD123 preferentially via antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells and has been shown to induce potent in vitro ADCC against IL3RA-expressing AML blasts/LSC and to reduce leukemic cell growth in murine xenograft models of human AML. In addition, the antibody inhibits signaling by IL-3, the main ligand of CD123, to reduce the proliferation of leukemic progenitor cells.